Cargando…
Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma
OBJECTIVE: Only few studies have focused on tumor markers used in the preoperative diagnosis of endometriosis-related ovarian neoplasms, and previous studies have only assessed serum CA125 levels. This study investigated the significance of preoperative tumor markers and clinical characteristics in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362875/ https://www.ncbi.nlm.nih.gov/pubmed/32354795 http://dx.doi.org/10.1136/ijgc-2020-001210 |
_version_ | 1783559577432752128 |
---|---|
author | Shinmura, Hiroki Yoneyama, Koichi Harigane, Eika Tsunoda, Yohei Fukami, Takehiko Matsushima, Takashi Takeshita, Toshiyuki |
author_facet | Shinmura, Hiroki Yoneyama, Koichi Harigane, Eika Tsunoda, Yohei Fukami, Takehiko Matsushima, Takashi Takeshita, Toshiyuki |
author_sort | Shinmura, Hiroki |
collection | PubMed |
description | OBJECTIVE: Only few studies have focused on tumor markers used in the preoperative diagnosis of endometriosis-related ovarian neoplasms, and previous studies have only assessed serum CA125 levels. This study investigated the significance of preoperative tumor markers and clinical characteristics in distinguishing endometriosis-related ovarian neoplasms from ovarian endometrioma. METHODS: A case-control study was conducted on 283 women who were diagnosed with confirmed pathology with endometriosis-related ovarian neoplasms (n=21) and ovarian endometrioma (n=262) at a single institution from April 2008 to April 2018. The serum CA125, CA19–9, carcinoembryogenic antigen (CEA), sialyl Lewis-x antigen (SLX), and lactate dehydrogenase (LDH) levels, age, tumor size, and the presence of mural nodule of the patients were analyzed. RESULTS: Patients with endometriosis-related ovarian neoplasms were more likely to be older (48 (range, 26–81) vs 39 (range, 22–68) years, P<0.001), have higher levels of CA19–9 (42 vs 19 U/mL, P=0.013), CEA (1.3 vs 0.84 ng/mL, P=0.007), SLX (41 vs 33 U/mL, P=0.050), and LDH (189 vs 166 U/mL, P<0.001) and larger tumor size (79 vs 55 mm, P=0.001), and present with mural nodule (85.7 vs 4.5 %, P<0.001) than those with ovarian endometrioma. The CA125 levels did not significantly differ between the two groups. The area under the curve for each factor was as follows: CA19-9 level, 0.672 (95% CI 0.52 to 0.83; P=0.013); CEA level, 0.725 (95% CI 0.58 to 0.87; P=0.007); SLX level, 0.670 (95% CI 0.53 to 0.84; P=0.050); LDH level, 0.800 (95% CI 0.70 to 0.90; P<0.001); age, 0.775 (95% CI 0.65 to 0.90; P<0.001); and tumor size, 0.709 (95% CI 0.56 to 0.86; P=0.001). Age was a better marker than CA19-9, CEA, and SLX levels according to the receiver operating characteristic curve analysis. The optimal cut-off values for age and tumor size were 47 years and 80 mm, respectively. CONCLUSIONS: The assessment of serum CA19–9, CEA, SLX, and LDH levels may be a useful tool in the preoperative evaluation to differentiate between endometriosis-related ovarian neoplasms and ovarian endometrioma. |
format | Online Article Text |
id | pubmed-7362875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-73628752020-07-16 Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma Shinmura, Hiroki Yoneyama, Koichi Harigane, Eika Tsunoda, Yohei Fukami, Takehiko Matsushima, Takashi Takeshita, Toshiyuki Int J Gynecol Cancer Original Research OBJECTIVE: Only few studies have focused on tumor markers used in the preoperative diagnosis of endometriosis-related ovarian neoplasms, and previous studies have only assessed serum CA125 levels. This study investigated the significance of preoperative tumor markers and clinical characteristics in distinguishing endometriosis-related ovarian neoplasms from ovarian endometrioma. METHODS: A case-control study was conducted on 283 women who were diagnosed with confirmed pathology with endometriosis-related ovarian neoplasms (n=21) and ovarian endometrioma (n=262) at a single institution from April 2008 to April 2018. The serum CA125, CA19–9, carcinoembryogenic antigen (CEA), sialyl Lewis-x antigen (SLX), and lactate dehydrogenase (LDH) levels, age, tumor size, and the presence of mural nodule of the patients were analyzed. RESULTS: Patients with endometriosis-related ovarian neoplasms were more likely to be older (48 (range, 26–81) vs 39 (range, 22–68) years, P<0.001), have higher levels of CA19–9 (42 vs 19 U/mL, P=0.013), CEA (1.3 vs 0.84 ng/mL, P=0.007), SLX (41 vs 33 U/mL, P=0.050), and LDH (189 vs 166 U/mL, P<0.001) and larger tumor size (79 vs 55 mm, P=0.001), and present with mural nodule (85.7 vs 4.5 %, P<0.001) than those with ovarian endometrioma. The CA125 levels did not significantly differ between the two groups. The area under the curve for each factor was as follows: CA19-9 level, 0.672 (95% CI 0.52 to 0.83; P=0.013); CEA level, 0.725 (95% CI 0.58 to 0.87; P=0.007); SLX level, 0.670 (95% CI 0.53 to 0.84; P=0.050); LDH level, 0.800 (95% CI 0.70 to 0.90; P<0.001); age, 0.775 (95% CI 0.65 to 0.90; P<0.001); and tumor size, 0.709 (95% CI 0.56 to 0.86; P=0.001). Age was a better marker than CA19-9, CEA, and SLX levels according to the receiver operating characteristic curve analysis. The optimal cut-off values for age and tumor size were 47 years and 80 mm, respectively. CONCLUSIONS: The assessment of serum CA19–9, CEA, SLX, and LDH levels may be a useful tool in the preoperative evaluation to differentiate between endometriosis-related ovarian neoplasms and ovarian endometrioma. BMJ Publishing Group 2020-06 2020-04-30 /pmc/articles/PMC7362875/ /pubmed/32354795 http://dx.doi.org/10.1136/ijgc-2020-001210 Text en © IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Shinmura, Hiroki Yoneyama, Koichi Harigane, Eika Tsunoda, Yohei Fukami, Takehiko Matsushima, Takashi Takeshita, Toshiyuki Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma |
title | Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma |
title_full | Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma |
title_fullStr | Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma |
title_full_unstemmed | Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma |
title_short | Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma |
title_sort | use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362875/ https://www.ncbi.nlm.nih.gov/pubmed/32354795 http://dx.doi.org/10.1136/ijgc-2020-001210 |
work_keys_str_mv | AT shinmurahiroki useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma AT yoneyamakoichi useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma AT hariganeeika useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma AT tsunodayohei useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma AT fukamitakehiko useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma AT matsushimatakashi useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma AT takeshitatoshiyuki useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma |